Sudarshan Chemical


CMP (NSE) 15:52, 11 Jun

689.25 -7.45-1.07%





Add to


Add to


Reco. Price




Target Price




Stop Loss


Last updated on

28 Aug, 2020

Sudarshan Chemical Industries (SCIL) has grown to become India’s largest manufacturer of colour pigments. Its estimated market share in India stands at ~35%. The company’s product portfolio comprises organic, inorganic and effect pigments serving four main end-uses: coatings, plastics, inks and cosmetics.
Having steadily gained market share and become the world’s 4th-largest colour pigment producer SCIL is well-placed to continue rapid growth in the context of the imminent exit of its two largest global competitors (BASF and Clariant).
The company’s low-cost manufacturing advantage, technical capabilities, wide product portfolio, growing client relationships, and environmental compliance are its key strengths. Input cost pressures, which impacted FY19 financials, are now fading. SCIL has a Capex plan worth Rs10bn for the next few years, which is expected to drive incremental revenues of ~Rs40bn and RoCE of ~30%. Capex will be oriented towards higher-value segments (high-performance pigments) with a superior margin profile.
Management guided an improved performance in 2Q on the back of a pick-up in domestic demand (to ~90% of pre-Covid levels vs. ~60% in 1Q) and resumption of plant operations post mid-July.
However, new orders and capex are delayed by ~6 months due to labour shortages, travel restrictions and other bottlenecks. Our positive stance remains predicated on the longer-term growth story.
We raise FY21ii EPS by 9% to Rs17.0 post the 1Q earnings beat but leave FY22/23ii EPS largely unchanged at Rs23.7/Rs31.6.
Technically, the stock is on a verge of giving a long-term bullish Cup & Handle breakout on the weekly chart, further accentuating our bullish stance on the stock.  We recommend a buy on Sudarshan Chemicals with a target price of  Rs557 (~20x Sep-22ii P/E).

Index vs Stock Relative Chart

Please refer to Research Disclaimer for additional recommendation parameter, analyst disclaimer and other disclosures.